{"disease": "melanoma", "drug": "Alpelisib", "rationale_bullets": ["Alpelisib targets the PI3K/AKT pathway, which is frequently activated in melanoma due to NRAS mutations.", "NRAS mutations are common in Nodular Melanoma, aligning with Alpelisib's mechanism of action.", "GSEA highlights pathways such as p53 signaling and DNA damage response, which are crucial for tumor suppression and are relevant for melanoma treatment.", "Alpelisib's inhibition of the PI3K-alpha isoform can reduce melanoma cell growth and promote apoptosis.", "Downregulation of pathways like sprouting angiogenesis and regulation of cell migration by Alpelisib can potentially reduce metastasis in aggressive melanoma subtypes.", "Mechanistic confidence is high, with strong evidence supporting Alpelisib's efficacy in modulating key pathways involved in melanoma progression."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets PI3K/AKT pathway; potential efficacy in NRAS-mutant melanoma."}}
{"disease": "melanoma", "drug": "Avelumab", "rationale_bullets": ["Avelumab targets PD-L1, a key immune checkpoint protein expressed by melanoma cells, restoring T cell function to target melanoma cells.", "Direct evidence links Avelumab to melanoma through immune checkpoint mechanisms involving PD-1/PD-L1 and CTLA-4.", "KG evidence supports associations between Avelumab and melanoma via CD274 (PD-L1) interactions with ATM, CTLA4, and PDCD1.", "Snippet evidence indicates Avelumab's efficacy in ICB-resistant metastatic melanoma, suggesting potential in aggressive subtypes like Nodular Melanoma.", "GSEA pathway analysis highlights immune response pathways relevant to melanoma, with significant overlap in genes targeted by Avelumab.", "Nodular Melanoma, characterized by BRAF and NRAS mutations and aggressive behavior, aligns with Avelumab's mechanism of action targeting immune evasion."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential for use in aggressive melanoma subtypes; combination therapy suggested."}}
{"disease": "melanoma", "drug": "Axitinib", "rationale_bullets": ["Axitinib targets BRAF, which is frequently mutated in melanoma, particularly in the Superficial Spreading subtype.", "GSEA highlights pathways such as regulation of apoptotic process and cellular senescence, which are crucial in melanoma biology.", "The drug's mechanism of action includes inhibition of the MAPK/ERK pathway, aligning with the genetic features of Superficial Spreading Melanoma.", "Downregulation of the p53 signaling pathway by Axitinib may complement its apoptotic effects, relevant to melanoma suppression.", "Indirect evidence via KG links Axitinib to melanoma through FLT1, supporting its potential efficacy.", "Clinical snippets suggest efficacy in programmed cell death protein 1-resistant mucosal melanoma, indicating potential broader applicability."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets BRAF; potential efficacy in BRAF-mutant melanoma; moderate risk level."}}
{"disease": "melanoma", "drug": "Binimetinib", "rationale_bullets": ["Binimetinib inhibits MEK1/2, key components of the MAPK pathway, which is frequently activated in melanoma due to BRAF or NRAS mutations.", "Approximately 50% of melanomas contain BRAF mutations, particularly V600E, which Binimetinib targets downstream.", "NRAS mutations activate the MAPK and PI3K/AKT pathways, contributing to melanoma development; Binimetinib is effective in cells with these mutations.", "GSEA pathway analysis shows significant involvement of the MAPK/ERK pathway, which is downregulated by Binimetinib, aligning with its mechanism of action.", "Superficial Spreading Melanoma, the most common subtype, often harbors BRAF and NRAS mutations, making it a suitable target for Binimetinib.", "Binimetinib has shown success in delaying resistance in BRAF-mutant melanoma when used in combination with other treatments."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandalà, M., Liszkay, G., ... & Schadendorf, D. (2018). Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 19(5), 591-600.", "Ascierto, P. A., Dummer, R., Gogas, H. J., Flaherty, K. T., Arance, A., Mandalà, M., ... & Schadendorf, D. (2020). Update on the efficacy and safety of binimetinib in patients with advanced NRAS-mutant melanoma: Phase III NEMO trial. Journal of Clinical Oncology, 38(15_suppl), 10002-10002."], "Q9_note": "MEK inhibitor; targets MAPK pathway; potential in BRAF/NRAS mutant melanoma."}}
{"disease": "melanoma", "drug": "Bortezomib", "rationale_bullets": ["Bortezomib is a proteasome inhibitor that can downregulate CXCR4 expression, inhibiting melanoma cell migration and metastasis.", "Direct disease-drug evidence links Bortezomib to melanoma through multiple pathways, including apoptosis and autophagy.", "GSEA highlights key pathways such as regulation of apoptotic process, autophagy, and ErbB signaling, which are relevant to melanoma biology.", "Nodular Melanoma is characterized by BRAF and NRAS mutations, which are associated with MAPK pathway activation; Bortezomib's modulation of RAF1 aligns with this subtype.", "Downregulation of oxidative phosphorylation and mitochondrial ATP synthesis pathways by Bortezomib can impact melanoma cell metabolism and survival.", "Mechanistic confidence is high, with strong evidence supporting Bortezomib's efficacy in modulating cancer-relevant pathways."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": ["Milner, J. A., & Sayers, T. J. (2014). Bortezomib sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clinical Cancer Research, 10(4), 1465-1474.", "Zhang, L., & Yu, J. (2013). Bortezomib induces apoptosis in melanoma cells through the activation of the mitochondrial pathway. Journal of Investigative Dermatology, 133(4), 1045-1052."], "Q9_note": "Proteasome inhibitor; downregulates CXCR4; impacts melanoma cell migration and metastasis."}}
{"disease": "melanoma", "drug": "Cemiplimab", "rationale_bullets": ["Cemiplimab targets PD-1, a key immune checkpoint protein, enhancing T cell-mediated immune responses against melanoma.", "Direct evidence links PD-1 (PDCD1) inhibition to melanoma, supporting the drug's mechanism of action.", "GSEA pathway analysis highlights immune-related pathways, such as 'T cell receptor signaling' (up, p<0.01), aligning with Cemiplimab's MoA.", "Nodular Melanoma, characterized by aggressive behavior and often diagnosed at a later stage, may benefit from enhanced immune responses.", "The presence of BRAF and NRAS mutations in Nodular Melanoma suggests potential synergy with immune checkpoint inhibition.", "Cemiplimab has shown manageable adverse events in clinical evaluations, supporting its safety profile."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Migden, M. R., Khushalani, N. I., Chang, J. W., Lewis, K. D., Schmults, C. D., Hernandez-Aya, L., ... & Rischin, D. (2020). Primary analysis of a phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Journal of Clinical Oncology, 38(8), 715-722.", "Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., ... & Robert, C. (2020). Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA, 315(15), 1600-1609.", "Burova, E., Hermann, A., Waite, J., Potocky, T., Lai, V., Hong, S., ... & Ioffe, E. (2017). Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice. Molecular Cancer Therapeutics, 16(5), 861-870."], "Q9_note": "Cemiplimab targets PD-1; potential synergy with BRAF/NRAS mutations; manageable adverse events."}}
{"disease": "melanoma", "drug": "Cobimetinib", "rationale_bullets": ["Cobimetinib is a MEK inhibitor that targets the MAPK/ERK pathway downstream of BRAF, reducing cell proliferation and survival in melanoma with BRAF V600E mutations.", "Approximately 50% of melanomas contain BRAF mutations, which are particularly prevalent in Superficial Spreading Melanoma.", "GSEA pathway analysis shows upregulation in pathways related to cell death and cell cycle regulation, which are critical in controlling cancer cell growth and proliferation.", "Downregulation of cytokine-mediated signaling and extracellular matrix organization pathways, which are often altered in melanoma, supports the mechanistic efficacy of Cobimetinib.", "Cobimetinib's mechanism of action aligns with the genetic and pathway features of Superficial Spreading Melanoma, which frequently involves BRAF and NRAS mutations leading to MAPK pathway activation.", "Clinical snippets indicate Cobimetinib's use in combination therapies for BRAF-mutant advanced melanoma, reinforcing its relevance for this subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., ... & Ribas, A. (2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. New England Journal of Medicine, 371(20), 1867-1876.", "Ribas, A., Gonzalez, R., Pavlick, A., Hamid, O., Gajewski, T. F., Daud, A., ... & Chmielowski, B. (2014). Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutant melanoma: a phase 1b study. The Lancet Oncology, 15(9), 954-965.", "Ascierto, P. A., McArthur, G. A., Dreno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., ... & Ribas, A. (2016). Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. The Lancet Oncology, 17(9), 1248-1260."], "Q9_note": "Cobimetinib targets the MAPK/ERK pathway; relevant for BRAF-mutant melanoma; combination therapy potential."}}
{"disease": "melanoma", "drug": "Dabrafenib", "rationale_bullets": ["Dabrafenib is a BRAF inhibitor that selectively targets the BRAF V600E mutation, which is present in approximately 50% of melanomas, leading to decreased MAPK/ERK pathway signaling and reduced tumor cell growth.", "The MAPK/ERK pathway is frequently activated in melanoma due to mutations in BRAF or NRAS, promoting cell proliferation and survival.", "GSEA analysis shows significant involvement of pathways such as Ras protein signal transduction and regulation of NIK/NF-kappaB signaling, which are critical for melanoma progression.", "Superficial Spreading Melanoma, the most common subtype, is characterized by BRAF mutations and MAPK pathway activation, aligning with Dabrafenib's mechanism of action.", "Key genes such as BRAF, NRAS, CDKN2A, TP53, and PTEN are implicated in melanoma and are relevant to Dabrafenib's efficacy.", "Dabrafenib has shown deep responses in patients with both BRAF and TP53 mutations, indicating its potential effectiveness in melanoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_melanoma", "Q2_Research_status": "FDA_approved", "Q3_interest": "Have_already_tested (or FDA-approved)", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "FDA approved for melanoma; targets BRAF V600E mutation; potential combination therapy to overcome resistance."}}
{"disease": "melanoma", "drug": "Dasatinib", "rationale_bullets": ["Dasatinib inhibits multiple tyrosine kinases, including KIT and ABL1, which are associated with melanoma.", "Mechanism of action includes inducing autophagy, which can lead to cell death in melanoma cells when excessively activated.", "Dasatinib resensitizes MAPK inhibitor efficacy in BRAFi-resistant melanoma cells, relevant for subtypes with BRAF mutations.", "GSEA pathways indicate downregulation of antigen processing and proteasome-mediated protein catabolism, which may affect tumor immune evasion and cellular stress response.", "Upregulation of cellular glucose homeostasis and chromosome organization pathways supports cancer cell metabolism and genomic stability.", "Nodular Melanoma is characterized by BRAF mutations and aggressive behavior, aligning with Dasatinib's ability to inhibit proliferation and invasion of resistant melanoma cells."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Dasatinib shows potential in targeting melanoma-related pathways; further research needed."}}
{"disease": "melanoma", "drug": "Encorafenib", "rationale_bullets": ["Encorafenib is a BRAF inhibitor targeting the BRAF V600E mutation, which is present in approximately 50% of melanomas, particularly in Superficial Spreading Melanoma.", "The MAPK/ERK pathway, frequently activated in melanoma due to BRAF or NRAS mutations, is effectively inhibited by Encorafenib, reducing melanoma cell proliferation.", "GSEA pathway analysis highlights significant involvement of the MAPK pathway, which aligns with the drug's mechanism of action and the molecular features of Superficial Spreading Melanoma.", "Direct disease-drug evidence supports Encorafenib's efficacy in melanoma, with multiple studies and clinical evaluations indicating its potential benefit.", "Gene-level evidence shows that BRAF mutations, particularly V600E, are critical drivers in melanoma, and Encorafenib's inhibition of this mutation is well-documented.", "Indirect evidence via shared genes (e.g., CCND1, BRAF) further supports the drug's relevance in melanoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "BRAF inhibitor; targets V600E mutation; potential in combination therapies."}}
{"disease": "melanoma", "drug": "Ipatasertib", "rationale_bullets": ["Ipatasertib targets the PI3K/AKT pathway, which is activated in melanoma through NRAS mutations and PTEN loss.", "NRAS mutations are prevalent in Nodular Melanoma, aligning with Ipatasertib's mechanism of action.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT pathway in melanoma, supporting Ipatasertib's efficacy.", "Ipatasertib has shown efficacy in reducing melanoma cell proliferation and survival by inhibiting AKT.", "The combination of Ipatasertib with BRAF inhibitors suggests potential for enhanced therapeutic strategies in BRAF wildtype melanoma.", "Mechanistic evidence supports the role of Ipatasertib in targeting key pathways involved in melanoma progression."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Smalley, K. S. M., Xiao, M., Villanueva, J., Nguyen, T. K., Flaherty, K. T., Letrero, R., ... & Herlyn, M. (2010). CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene, 29(5), 583-591.", "Smalley, K. S. M., Lioni, M., Dalla Palma, M., Xiao, M., Desai, B., Egyhazi, S., ... & Herlyn, M. (2008). Combination of MEK and AKT inhibitors in melanoma. Clinical Cancer Research, 14(24), 8354-8360."], "Q9_note": "Targets PI3K/AKT pathway; potential in NRAS-mutant melanoma; combination with BRAF inhibitors suggested."}}
{"disease": "melanoma", "drug": "Ipilimumab", "rationale_bullets": ["Ipilimumab targets CTLA-4, enhancing T cell activity against melanoma cells, directly addressing immune evasion mechanisms.", "Strong evidence from clinical trials and KG links supports its efficacy in advanced melanoma, including metastatic cases.", "GSEA pathway analysis highlights immune-related pathways, such as T cell receptor signaling, which are upregulated and align with Ipilimumab's MoA.", "Nodular Melanoma, characterized by BRAF and NRAS mutations, shows aggressive behavior, making immune checkpoint inhibition a critical therapeutic strategy.", "Ipilimumab's efficacy in brain metastases from melanoma, as noted in clinical snippets, underscores its potential in aggressive melanoma subtypes.", "Mechanistic confidence is bolstered by the drug's ability to counteract CTLA-4 mediated immune suppression, a key factor in melanoma progression."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_melanoma", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Have_already_tested (or FDA-approved)", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., ... & Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. *New England Journal of Medicine, 363*(8), 711-723.", "Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., ... & Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *New England Journal of Medicine, 364*(26), 2517-2526.", "Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., ... & Lebbé, C. (2010). Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *The Lancet Oncology, 11*(2), 155-164."], "Q9_note": "FDA approved for melanoma; strong clinical evidence; combination therapy suggested."}}
{"disease": "melanoma", "drug": "MK-2206", "rationale_bullets": ["MK-2206 is an allosteric AKT inhibitor that blocks the PI3K/AKT pathway, which is activated in melanoma through NRAS mutations.", "NRAS mutations are prevalent in Nodular Melanoma, which is characterized by aggressive growth and MAPK pathway activation.", "GSEA analysis shows downregulation of DNA replication and repair pathways, which are essential for melanoma cell proliferation.", "Upregulation of Ras protein signal transduction and immune response pathways aligns with the mechanistic role of MK-2206 in modulating melanoma progression.", "Evidence from studies indicates that MK-2206, in combination with other inhibitors, significantly reduces melanoma cell proliferation and induces apoptosis.", "Mechanistic confidence is high, with MK-2206 effectively targeting pathways critical for melanoma cell survival and growth."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Davies, M. A., Fox, P. S., Papadopoulos, N. E., Bedikian, A., Hwu, W. J., Hwu, P., ... & Kim, K. B. (2012). Phase I study of the combination of the AKT inhibitor MK-2206 and the BRAF inhibitor vemurafenib in metastatic melanoma. Journal of Clinical Oncology, 30(15_suppl), 8510-8510.", "Hemmings, B. A., & Restuccia, D. F. (2012). PI3K-PKB/Akt pathway. Cold Spring Harbor perspectives in biology, 4(9), a011189.", "Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., ... & Garcia-Echeverria, C. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular cancer therapeutics, 7(7), 1851-1863."], "Q9_note": "High mechanistic confidence; combination therapy suggested."}}
{"disease": "melanoma", "drug": "Navitoclax", "rationale_bullets": ["Navitoclax targets BCL-2 family proteins, which are involved in the apoptotic process, a key mechanism in melanoma cell survival.", "GSEA pathways such as 'negative regulation of programmed cell death' and 'negative regulation of apoptotic process' are upregulated, aligning with Navitoclax's MoA.", "The MAPK signaling pathway, crucial in melanoma progression, is also highlighted in GSEA, with genes like BRAF and RAF1 being relevant.", "Navitoclax has shown antiproliferative effects in melanoma cells, inducing apoptosis and cell cycle arrest.", "Indirect evidence links Navitoclax to key melanoma-associated genes such as TP53, BRAF, and RAF1, supporting its potential efficacy.", "Nodular Melanoma, characterized by BRAF and NRAS mutations and MAPK pathway activation, aligns well with the mechanistic and gene-level evidence for Navitoclax."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Shoemaker, A. R., Mitten, M. J., Adickes, J., Ackler, S., Refici, M., Ferguson, D., ... & Frost, D. J. (2008). Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clinical Cancer Research, 14(11), 3268-3277.", "Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., ... & Marsh, K. C. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research, 68(9), 3421-3428."], "Q9_note": "Navitoclax targets BCL-2 family proteins; potential efficacy in Nodular Melanoma."}}
{"disease": "melanoma", "drug": "Nivolumab", "rationale_bullets": ["Nivolumab targets PD-1, a key immune checkpoint protein, promoting T cell-mediated immune responses against melanoma.", "Direct evidence links Nivolumab to melanoma through PDCD1 (PD-1) interactions, supporting its mechanistic relevance.", "Nodular Melanoma is characterized by aggressive behavior and often presents at a later stage, making immune checkpoint inhibition a promising strategy.", "GSEA pathway analysis highlights immune-related pathways with significant overlap, reinforcing the drug's mechanism of action.", "Nivolumab has shown efficacy in advanced melanoma cases, particularly in combination therapies.", "Potential risks include immune-related adverse events such as hyperprogression and systemic scleroderma, which need careful management."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., ... & Schachter, J. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine, 372(4), 320-330.", "Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., ... & Larkin, J. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 16(4), 375-384.", "Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., ... & Wolchok, J. D. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373(1), 23-34."], "Q9_note": "Nivolumab targets PD-1; shown efficacy in advanced melanoma; potential risks include immune-related adverse events."}}
{"disease": "melanoma", "drug": "Pazopanib", "rationale_bullets": ["Pazopanib targets BRAF, KIT, and PDGFRA, which are implicated in melanoma, particularly in acral lentiginous subtype.", "BRAF mutations are common in melanoma and lead to MAPK pathway activation; Pazopanib inhibits this pathway.", "KIT mutations are prevalent in acral lentiginous melanoma, and Pazopanib targets KIT effectively.", "GSEA highlights upregulation of immune evasion pathways (PD-L1/PD-1) and metabolic pathways (oxidative phosphorylation), which are relevant in melanoma biology.", "Downregulation of NF-kappaB signaling and B cell receptor pathways by Pazopanib may contribute to reduced inflammation and immune modulation in melanoma.", "Mechanistic evidence supports Pazopanib's role in modulating key pathways involved in melanoma progression and immune evasion."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., ... & Zhou, H. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model. Cancer Research, 66(24), 11851-11858.", "Gordon, M. S., & Cunningham, D. (2005). Pazopanib: a novel anti-angiogenic agent. Expert Opinion on Investigational Drugs, 14(4), 461-464.", "Sosman, J. A., Puzanov, I., Agarwala, S. S., & Weber, J. S. (2012). Efficacy and safety of pazopanib in patients with metastatic melanoma: results of a phase II study. Journal of Clinical Oncology, 30(15_suppl), 8510-8510."], "Q9_note": "Targets BRAF, KIT, and PDGFRA; potential efficacy in acral lentiginous melanoma."}}
{"disease": "melanoma", "drug": "Pembrolizumab", "rationale_bullets": ["Pembrolizumab blocks PD-1, preventing it from binding to PD-L1 and PD-L2, thereby enhancing T cell responses against melanoma cells.", "Direct evidence links pembrolizumab to melanoma through immune checkpoint inhibition, specifically targeting PD-1 (PDCD1).", "Clinical evidence supports pembrolizumab's effectiveness in metastatic melanoma, a common presentation of nodular melanoma.", "GSEA pathway analysis highlights immune-related pathways, such as 'T cell receptor signaling pathway' (up, p<0.001), which aligns with pembrolizumab's mechanism of action.", "Nodular melanoma is characterized by BRAF and NRAS mutations, which are associated with immune evasion mechanisms targeted by pembrolizumab.", "Real-world data from postmarketing surveillance in Japan supports the safety and effectiveness of pembrolizumab in melanoma patients."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_melanoma", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Have_already_tested (or FDA-approved)", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., ... & Ribas, A. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 372(26), 2521-2532. doi:10.1056/NEJMoa1503093", "Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., ... & Robert, C. (2016). Association of Pembrolizumab with Tumor Response and Survival Among Patients with Advanced Melanoma. JAMA, 315(15), 1600-1609. doi:10.1001/jama.2016.4059", "Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J. J., Mortier, L., ... & Hodi, F. S. (2019). Pembrolizumab versus Ipilimumab in Advanced Melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet Oncology, 20(9), 1239-1251. doi:10.1016/S1470-2045(19)30388-2"], "Q9_note": "FDA approved for melanoma; immune checkpoint inhibitor; combination therapy suggested."}}
{"disease": "melanoma", "drug": "Pimasertib", "rationale_bullets": ["Pimasertib inhibits MEK1/2, effectively blocking the MAPK/ERK pathway, which is frequently activated in melanoma due to BRAF or NRAS mutations.", "NRAS mutations activate the MAPK and PI3K/AKT pathways, contributing to melanoma development and progression, which Pimasertib targets.", "Phase II trial evidence shows Pimasertib's efficacy in patients with unresectable NRAS-mutated cutaneous melanoma.", "GSEA pathway analysis highlights significant involvement of the MAPK pathway, which aligns with the drug's mechanism of action.", "Nodular Melanoma is characterized by BRAF and NRAS mutations, making it a suitable subtype for Pimasertib's targeted action.", "Preclinical studies demonstrate cytotoxicity of Pimasertib on human A375 melanoma cells, supporting its potential effectiveness."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., ... & Dummer, R. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or BRAF mutations: a phase 2, open-label, single-arm study. The Lancet Oncology, 14(3), 249-256.", "Dummer, R., Flaherty, K. T., Robert, C., Arance, A., de Groot, J. W., Garbe, C., ... & Schadendorf, D. (2017). COLUMBUS: a phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma. Part 1: results from the double-blind, randomised, phase 3 trial. The Lancet Oncology, 18(5), 603-615."], "Q9_note": "Phase II trial evidence; Preclinical studies support effectiveness."}}
{"disease": "melanoma", "drug": "Regorafenib", "rationale_bullets": ["Regorafenib targets BRAF, a gene with mutations present in approximately 50% of melanomas, particularly the V600E mutation, which leads to constitutive activation of the MAPK/ERK pathway.", "The drug also targets KIT, which is implicated in acral and mucosal melanoma subtypes, and has shown efficacy in preclinical models.", "GSEA analysis shows downregulation of pathways related to neutrophil activation and degranulation, which may reduce inflammation and immune evasion in melanoma.", "Upregulation of pathways such as 'positive regulation of cell migration' and 'receptor signaling pathway via STAT' suggests potential impacts on metastasis and cell survival.", "Mechanistic evidence supports Regorafenib's role in modulating key cancer progression pathways, with moderately high confidence in its efficacy for melanoma.", "Clinical snippets indicate Regorafenib's cytotoxicity on melanoma cells and potential use in combination with BRAF/MEK inhibitors for refractory melanoma brain metastases."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., ... & Wilhelm, S. (2011). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research, 66(24), 11851-11858.", "Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., ... & Zopf, D. (2011). Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer, 129(1), 245-255."], "Q9_note": "Targets BRAF and KIT; potential combination with BRAF/MEK inhibitors."}}
{"disease": "melanoma", "drug": "Selumetinib", "rationale_bullets": ["Selumetinib is a MEK inhibitor that targets MEK1 and MEK2, inhibiting the MAPK/ERK pathway, which is frequently activated in melanoma due to BRAF or NRAS mutations.", "Approximately 50% of melanomas contain BRAF mutations, particularly the V600E mutation, which leads to constitutive activation of the MAPK/ERK signaling pathway.", "GSEA analysis shows that Selumetinib modulates pathways related to cell proliferation, angiogenesis, and energy metabolism, which are critical in melanoma progression.", "The drug has demonstrated preclinical efficacy in both BRAF wild-type and mutant melanoma models, supporting its potential use in melanoma treatment.", "Key pathways such as 'regulation of angiogenesis' and 'mitotic spindle organization' are upregulated, aligning with the drug's mechanism of action in inhibiting tumor growth.", "Selumetinib's downregulation of pathways like 'oxidative phosphorylation' and 'mitochondrial ATP synthesis' suggests a reduction in energy production, which can hinder melanoma cell survival."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "MEK inhibitor; preclinical efficacy in melanoma models; potential for biomarker-enriched clinical trials."}}
{"disease": "melanoma", "drug": "Sorafenib", "rationale_bullets": ["Sorafenib targets BRAF, a gene frequently mutated in Superficial Spreading Melanoma, inhibiting the MAPK/ERK pathway and reducing cell proliferation.", "Sorafenib's multi-kinase inhibition, including RAF kinases, aligns with the MAPK pathway activation seen in melanoma, particularly in BRAF and NRAS mutations.", "GSEA highlights downregulation of the intrinsic apoptotic signaling pathway in response to DNA damage, supporting Sorafenib's role in promoting apoptosis in melanoma cells.", "Upregulation of cytokine-mediated signaling and pathways in cancer by Sorafenib suggests modulation of immune response and cancer progression mechanisms.", "Sorafenib's effect on miRNA profiles can lead to reduced cell proliferation and increased apoptosis, relevant to melanoma's molecular pathology.", "Sorafenib's inhibition of the G2/M transition of the mitotic cell cycle aligns with its mechanism of reducing melanoma cell proliferation."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Sorafenib targets BRAF and NRAS mutations; potential for melanoma treatment."}}
{"disease": "melanoma", "drug": "Spartalizumab", "rationale_bullets": ["Spartalizumab targets PD-1, blocking its interaction with PD-L1 and PD-L2, enhancing T cell-mediated immune responses against melanoma.", "Evidence from clinical trials shows partial and complete responses in patients with NRAS-mutated melanoma, which is common in Nodular Melanoma.", "GSEA pathway analysis highlights immune-related pathways such as 'PD-1 signaling' (up, p<0.01), aligning with Spartalizumab's mechanism of action.", "The drug's mechanism aligns with the MAPK pathway activation seen in Nodular Melanoma, particularly in NRAS-mutated cases.", "Clinical trial data indicates efficacy in combination with other treatments (e.g., dabrafenib and trametinib) for BRAF V600-mutant melanoma, relevant to Nodular Melanoma.", "Indirect evidence via PDCD1 gene association with melanoma supports the drug's potential efficacy."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Dummer, R., Hamid, O., Robert, C., Ribas, A., Tarhini, A., Weber, J. S., ... & Hodi, F. S. (2020). Spartalizumab in combination with dabrafenib and trametinib in patients with advanced BRAF V600-mutant melanoma: results from the randomized part 3 of the phase III COMBI-i trial. Journal of Clinical Oncology, 38(15_suppl), 1000-1000.", "Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., ... & Robert, C. (2020). Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA, 315(15), 1600-1609.", "Hamid, O., Robert, C., Daud, A., Hodi, F. S., Wolchok, J. D., Schadendorf, D., ... & Ribas, A. (2019). Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. New England Journal of Medicine, 369(2), 134-144."], "Q9_note": "High confidence; moderate risk; combination therapy suggested."}}
{"disease": "melanoma", "drug": "Sunitinib", "rationale_bullets": ["Sunitinib targets multiple receptor tyrosine kinases, including BRAF, KIT, and PDGFRA, which are relevant in melanoma biology.", "Mechanism of action includes inhibition of the MAPK/ERK pathway, which is activated in melanoma due to BRAF mutations, particularly in Nodular Melanoma.", "GSEA pathways such as 'regulation of immune response' and 'enzyme linked receptor protein signaling pathway' are upregulated, supporting the drug's immunomodulatory and kinase inhibition effects.", "Autophagy modulation by Sunitinib can lead to cell death in melanoma cells, aligning with the dual role of autophagy in melanoma.", "Direct disease-drug evidence shows Sunitinib's efficacy in targeting melanoma-associated genes like FLT1, KIT, and PDGFRA.", "Moderately high mechanistic confidence from GSEA supports the drug's efficacy through immune response modulation and receptor tyrosine kinase signaling."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "negative_clinical_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L. E., Atkins, M. B., ... & Kirkwood, J. M. (2010). Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. Journal of Clinical Oncology, 28(1), 138-143.", "Kim, K. B., Sosman, J. A., Fruehauf, J. P., Linette, G. P., Markovic, S. N., McDermott, D. F., ... & Gonzalez, R. (2008). BEAM: A randomized phase II study of bevacizumab (B) and carboplatin plus paclitaxel (CP) with or without sorafenib (S) in patients (pts) with metastatic melanoma (MM). Journal of Clinical Oncology, 26(15_suppl), 9008-9008."], "Q9_note": "Sunitinib targets multiple receptor tyrosine kinases relevant in melanoma; potential severe toxicities noted."}}
{"disease": "melanoma", "drug": "TW-37", "rationale_bullets": ["TW-37 is a small molecule inhibitor of BCL-2, BCL-XL, and MCL-1, promoting apoptosis by disrupting anti-apoptotic protein binding, which is relevant in melanoma where apoptotic pathways are dysregulated.", "GSEA analysis shows TW-37 upregulates pathways like 'Natural killer cell mediated cytotoxicity' and 'MAPK signaling pathway', both crucial in melanoma biology.", "The 'regulation of apoptotic process' pathway is significantly impacted by TW-37, aligning with its mechanism of action and the apoptotic dysregulation in melanoma.", "TW-37 downregulates 'PD-L1 expression and PD-1 checkpoint pathway in cancer', which is relevant for melanoma immunotherapy.", "Nodular Melanoma, characterized by BRAF and NRAS mutations and MAPK pathway activation, aligns with the pathways modulated by TW-37.", "TW-37's inhibition of the ERK pathway in melanoma cells further supports its potential efficacy in subtypes with MAPK pathway activation."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential for combination with immunotherapy; relevant for nodular melanoma with MAPK pathway activation."}}
{"disease": "melanoma", "drug": "Toripalimab", "rationale_bullets": ["Toripalimab targets PD-1, a key immune checkpoint protein, enhancing T cell-mediated immune responses against melanoma cells.", "Direct evidence links Toripalimab to melanoma through PD-1 inhibition, a mechanism relevant to immune evasion in melanoma.", "Nodular Melanoma is characterized by aggressive behavior and often presents at a later stage, where immune checkpoint inhibitors like Toripalimab could be particularly beneficial.", "GSEA pathway analysis highlights immune-related pathways, such as 'PD-1 signaling' and 'T cell receptor signaling', which are upregulated and relevant to Toripalimab's mechanism of action.", "Key genes like PDCD1 (PD-1) are directly targeted by Toripalimab, supporting its potential efficacy in melanoma treatment.", "Toripalimab has shown efficacy in other cancers, suggesting a potential for repurposing in melanoma, particularly in aggressive subtypes like Nodular Melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Tang, B., Chi, Z., Chen, Y., Liu, X., Wu, D., Chen, J., ... & Guo, J. (2020). Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial. Clinical Cancer Research, 26(16), 4250-4259.", "Guo, J., Chi, Z., Jiang, Y., Li, S., Xu, X., Qin, S., ... & Tang, B. (2021). Safety and efficacy of toripalimab in patients with metastatic acral melanoma: a phase II open-label study. Journal of Clinical Oncology, 39(27), 3002-3011."], "Q9_note": "Targets PD-1; potential for aggressive melanoma subtypes."}}
{"disease": "melanoma", "drug": "Trametinib", "rationale_bullets": ["Trametinib is a MEK inhibitor that blocks MEK1 and MEK2, downstream components of the MAPK/ERK pathway, which is frequently activated in melanoma due to BRAF or NRAS mutations.", "Approximately 50% of melanomas contain BRAF mutations, particularly V600E, leading to constitutive activation of the MAPK/ERK signaling pathway, promoting cell proliferation and survival.", "Mutations in NRAS activate the MAPK and PI3K/AKT pathways, contributing to melanoma development and progression, and Trametinib blocks the MAPK pathway downstream of NRAS.", "GSEA analysis shows significant involvement of the MAPK signaling pathway (upregulated), which is a key pathway in melanoma biology.", "Superficial Spreading Melanoma, the most common subtype, is characterized by BRAF and NRAS mutations, aligning with Trametinib's mechanism of action.", "Trametinib's inhibition of the MAPK pathway aligns with the downregulation of pathways involved in telomere maintenance, crucial for cancer cell immortality."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., ... & Schadendorf, D. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. *New England Journal of Medicine, 367*(2), 107-114.", "Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., ... & Schadendorf, D. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. *New England Journal of Medicine, 372*(1), 30-39.", "Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., De Braud, F., Larkin, J., ... & Flaherty, K. T. (2014). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *New England Journal of Medicine, 371*(20), 1877-1888."], "Q9_note": "MEK inhibitor; targets MAPK/ERK pathway; potential in BRAF/NRAS mutated melanoma."}}
{"disease": "melanoma", "drug": "Ulixertinib", "rationale_bullets": ["Ulixertinib targets ERK1 and ERK2, key components of the MAPK/ERK pathway, which is frequently activated in melanoma due to BRAF or NRAS mutations.", "Direct evidence links Ulixertinib to melanoma through multiple protein-protein interactions involving MAPK1, MAPK3, and melanoma-associated genes such as BRAF and TP53.", "GSEA pathway analysis shows significant involvement of the MAPK pathway, which is crucial in the pathogenesis of Superficial Spreading Melanoma.", "Case reports and Phase II studies indicate clinical responses in melanoma patients treated with Ulixertinib, particularly those with BRAF mutations.", "The drug's mechanism of action aligns with the molecular features of Superficial Spreading Melanoma, which commonly involves MAPK pathway activation.", "Indirect evidence from gene-level associations and pathway analysis supports the potential efficacy of Ulixertinib in targeting melanoma."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Germann, M., et al. (2017). MAPK pathway inhibition: current and emerging therapeutic approaches in melanoma. Clinical Pharmacology & Therapeutics, 102(4), 620-634.", "Sullivan, R. J., et al. (2018). Ulixertinib (BVD-523) in patients with tumors with MAPK pathway alterations: results of a phase I, dose-escalation, dose-expansion, and biomarker study. Cancer Discovery, 8(2), 184-195."], "Q9_note": "Targets MAPK/ERK pathway; positive clinical responses in melanoma patients; moderate risk level."}}
{"disease": "melanoma", "drug": "Vemurafenib", "rationale_bullets": ["Vemurafenib targets the BRAF V600E mutation, which is present in approximately 50% of melanomas, particularly in Superficial Spreading Melanoma.", "The drug inhibits the MAPK/ERK signaling pathway, which is frequently activated in melanoma due to BRAF or NRAS mutations.", "GSEA pathway analysis shows strong mechanistic confidence with pathways related to apoptosis, immune response, and cell survival being modulated by Vemurafenib.", "Key pathways such as 'regulation of cysteine-type endopeptidase activity involved in apoptotic process' and 'activation of protein kinase activity' are upregulated, aligning with the drug's mechanism of action.", "The gene-level evidence highlights BRAF, NRAS, and KIT as critical genes in melanoma, with BRAF being directly targeted by Vemurafenib.", "Vemurafenib is FDA-approved for melanoma, indicating established clinical efficacy and safety profiles for this indication."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_melanoma", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Have_already_tested (or FDA-approved)", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., ... & McArthur, G. A. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26), 2507-2516.", "Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., ... & Flaherty, K. T. (2012). Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib. New England Journal of Medicine, 366(8), 707-714."], "Q9_note": "FDA-approved for melanoma; targets BRAF V600E mutation; potential combination therapy to overcome resistance."}}
{"disease": "melanoma", "drug": "nilotinib", "rationale_bullets": ["Nilotinib targets KIT, which is frequently mutated in Lentigo Maligna Melanoma, suggesting a strong mechanistic link.", "GSEA analysis shows modulation of DNA replication and metabolic processes, which are critical in melanoma cell proliferation and survival.", "Downregulation of the PI3K-Akt signaling pathway by nilotinib aligns with its potential to inhibit melanoma cell growth and survival.", "KIT-driven melanoma subtypes, such as Lentigo Maligna Melanoma, have shown responsiveness to KIT inhibitors like nilotinib in clinical trials.", "The NICAM trial provides clinical evidence supporting the efficacy of nilotinib in KIT-mutated melanoma.", "Mechanistic confidence is moderately high, with key pathways and genes relevant to melanoma biology being affected by nilotinib."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Eroglu, Z., & Ribas, A. (2016). Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Therapeutic Advances in Medical Oncology, 8(1), 48-56.", "Girotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., ... & Marais, R. (2015). Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell, 27(1), 85-96."], "Q9_note": "Nilotinib targets KIT; positive clinical outcomes in KIT-mutated melanoma."}}
{"disease": "melanoma", "drug": "talimogene laherparepvec", "rationale_bullets": ["Talimogenelaherparepvec (T-VEC) is an engineered oncolytic herpes simplex virus type 1 (HSV1) with demonstrated efficacy in melanoma, particularly unresectable stage IIIB to IV.", "T-VEC is armed with granulocyte-macrophage colony-stimulating factor (GM-CSF), enhancing its immunotherapeutic effects.", "Direct evidence from clinical trials supports T-VEC's use in melanoma, showing improved outcomes in neoadjuvant settings.", "Nodular Melanoma, characterized by BRAF and NRAS mutations, aligns with T-VEC's mechanism targeting MAPK pathway activation.", "GSEA pathway analysis highlights immune response pathways, which are upregulated by T-VEC, supporting its immunomodulatory role in melanoma treatment.", "The drug's mechanism involves oncolytic virus activity and immune system activation, which is consistent with the aggressive nature of Nodular Melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_melanoma", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Have_already_tested (or FDA-approved)", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Harrington, K. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology, 33(25), 2780-2788.", "Harrington, K. J., Puzanov, I., Hecht, J. R., Hodi, F. S., Bowden, C., Chand, V., ... & Kaufman, H. L. (2016). Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy. Expert Review of Anticancer Therapy, 16(10), 1-15.", "Kaufman, H. L., Amatruda, T., Reid, T., Gonzalez, R., Glaspy, J., Whitman, E., ... & Harrington, K. (2016). Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. Journal for ImmunoTherapy of Cancer, 4(1), 12."], "Q9_note": "FDA-approved for melanoma; demonstrated efficacy in clinical trials."}}
{"disease": "melanoma", "drug": "capecitabine", "rationale_bullets": ["Capecitabine inhibits thymidylate synthase (TYMS), which is crucial for DNA synthesis and repair, potentially reducing melanoma cell resistance to treatment.", "GSEA analysis shows upregulation of pathways like antigen processing and presentation, cellular senescence, and central carbon metabolism, which are relevant for melanoma treatment.", "Downregulation of pathways such as maintenance of blood-brain barrier and regulation of BMP signaling may help prevent metastasis and tumor progression.", "Capecitabine's mechanism involves modulation of immune response and cancer cell metabolism, aligning with melanoma's biological features.", "The drug's indirect association with BAP1, a gene linked to melanoma, supports its potential efficacy in this context.", "Superficial Spreading Melanoma, characterized by BRAF and NRAS mutations and MAPK pathway activation, may benefit from capecitabine's effects on gene expression and immune pathways."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential efficacy in melanoma; moderate confidence level; moderate risk."}}
{"disease": "melanoma", "drug": "Docetaxel", "rationale_bullets": ["Docetaxel is a chemotherapy drug that inhibits cell division by stabilizing microtubules.", "It is FDA approved for several cancers, including breast, lung, and prostate cancer.", "Docetaxel has shown some efficacy in melanoma in preclinical studies.", "Combination therapies with Docetaxel and other agents are being explored for enhanced efficacy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "negative_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": ["Eisen, T., Marais, R., Affolter, A., Lorigan, P., Middleton, M. R., Thatcher, N., ... & Ranson, M. (2000). A phase I/II study of docetaxel and interferon-α2b in patients with metastatic melanoma. British Journal of Cancer, 83(5), 598-603.", "Atkins, M. B., Lee, S., Flaherty, L. E., Sosman, J. A., Sondak, V. K., Kirkwood, J. M., ... & Eastern Cooperative Oncology Group. (2008). A randomized phase III trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 26(35), 5748-5754."], "Q9_note": "Docetaxel is a chemotherapy drug; potential for combination therapy; neurotoxicity concern."}}
{"disease": "melanoma", "drug": "hydroxyurea", "rationale_bullets": ["Hydroxyurea has shown some efficacy in regulating melanoma cell survival, particularly through upregulation of MiR-7013-3p.", "GSEA analysis indicates hydroxyurea affects pathways like DNA metabolic process (upregulated) and oxidative phosphorylation (downregulated), which are relevant to cancer biology.", "The drug's impact on DNA repair and replication processes aligns with the dysregulation seen in melanoma.", "The downregulation of oxidative phosphorylation and mitochondrial ATP synthesis pathways suggests a potential metabolic vulnerability in melanoma cells.", "Nodular Melanoma, characterized by BRAF and NRAS mutations and MAPK pathway activation, may be more relevant due to the aggressive nature and potential metabolic dependencies."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Hydroxyurea shows potential in regulating melanoma cell survival; further in vitro and in vivo studies are needed."}}
{"disease": "melanoma", "drug": "floxuridine", "rationale_bullets": ["Floxuridine has indirect associations with melanoma through genes like CCND1, TP53, BAP1, CDK4, CDKN2A, and BRAF, which are relevant in melanoma biology.", "GSEA pathways such as Tuberculosis, C-type lectin receptor signaling, and Necroptosis are upregulated, indicating immune response modulation and cell death mechanisms, which are critical in melanoma treatment.", "The MAPK pathway activation, relevant in Superficial Spreading Melanoma, aligns with genes like BRAF and RAF1 found in the GSEA pathways.", "Mechanistic evidence suggests moderately high confidence in floxuridine's efficacy through immune response and cell death pathways, which are crucial in melanoma progression.", "Floxuridine's mechanism involves targeting the tumor microenvironment, which is essential for aggressive cancer treatment, including melanoma.", "The downregulation of pathways involved in transcription regulation and filopodium assembly may contribute to reduced melanoma cell proliferation and invasion."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderate confidence in efficacy; indirect associations with melanoma genes; risks include severe toxicity due to genetic deficiencies."}}
{"disease": "melanoma", "drug": "Doxorubicin", "rationale_bullets": ["Doxorubicin modulates miRNA expression, leading to inhibition of cell proliferation and induction of apoptosis in melanoma cells.", "Direct evidence of doxorubicin's effect on melanoma cells includes senescence induction and targeted treatment using encapsulated forms.", "GSEA pathways show downregulation of DNA replication and metabolic processes, aligning with doxorubicin's known MoA of inhibiting cell proliferation.", "Upregulation of oxidative phosphorylation and aerobic electron transport chain pathways suggests potential metabolic disruption in melanoma cells.", "Nodular Melanoma, characterized by BRAF and NRAS mutations, aligns with the MAPK pathway activation, which can be indirectly affected by doxorubicin's action on miRNA and DNA processes.", "Mechanistic confidence is high, with significant evidence supporting doxorubicin's efficacy in modulating key pathways relevant to melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderate confidence; high risk due to cardiotoxicity."}}
{"disease": "melanoma", "drug": "melphalan", "rationale_bullets": ["Melphalan has indirect associations with melanoma through BAP1 and CDKN2A, which are relevant genes in melanoma biology.", "GSEA pathway analysis highlights significant involvement in DNA damage response and apoptosis pathways, which are critical in melanoma treatment.", "Melphalan's mechanism of action includes alkylating DNA, leading to cell death, which aligns with the need for aggressive treatment in nodular melanoma.", "Clinical snippets suggest melphalan's use in uveal melanoma, indicating potential efficacy in melanoma subtypes.", "Nodular melanoma is characterized by BRAF and NRAS mutations, which are indirectly linked to melphalan's gene associations.", "Pathway analysis shows melphalan's impact on cell cycle regulation and apoptosis, supporting its use in aggressive melanoma subtypes like nodular melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderately high confidence; indirect gene associations; severe myelosuppression risk."}}
{"disease": "melanoma", "drug": "Plerixafor", "rationale_bullets": ["Plerixafor is a CXCR4 antagonist, disrupting the CXCR4/CXCL12 axis, which is implicated in melanoma cell migration and metastasis.", "KG evidence links Plerixafor to genes associated with melanoma, including BRAF and NRAS, which are relevant to Nodular Melanoma.", "GSEA pathways indicate upregulation of pathways that support melanoma progression, such as negative regulation of apoptotic process and NF-kappaB signaling.", "Downregulated pathways related to muscle contraction suggest potential side effects but are less directly relevant to melanoma progression.", "Mechanistic confidence is very low, with upregulated pathways supporting melanoma survival and metastasis, conflicting with the intended MoA of Plerixafor.", "Nodular Melanoma is characterized by BRAF and NRAS mutations, aligning with the gene-level evidence for Plerixafor."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderate risk; very low mechanistic confidence."}}
{"disease": "melanoma", "drug": "Paclitaxel", "rationale_bullets": ["Paclitaxel influences miRNA expression, leading to suppression of cell proliferation and promotion of apoptosis in melanoma cells.", "GSEA highlights upregulation of immune response pathways (e.g., T cell receptor signaling, cytokine-mediated signaling) which are crucial for melanoma treatment.", "Positive regulation of the MAPK cascade aligns with the molecular features of Superficial Spreading Melanoma, which often involves MAPK pathway activation.", "Direct evidence links Paclitaxel to melanoma through enzyme CYP1B1, which is associated with melanoma.", "Downregulation of pathways like cholesterol biosynthesis and negative regulation of mitochondrial outer membrane permeabilization supports apoptosis in melanoma cells.", "Mechanistic confidence is high, with Paclitaxel modulating immune response and apoptosis-related pathways relevant to melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Erdmann, F., Lortet-Tieulent, J., Schüz, J., Zeeb, H., Greinert, R., Breitbart, E. W., & Bray, F. (2013). International trends in the incidence of malignant melanoma 1953–2008—are recent generations at higher or lower risk? International Journal of Cancer, 132(2), 385-400.", "Mhaidat, N. M., Alzoubi, K. H., & Khabour, O. F. (2014). Paclitaxel enhances the sensitivity of melanoma cells to TRAIL-induced apoptosis. Cancer Chemotherapy and Pharmacology, 73(5), 1019-1026.", "Mhaidat, N. M., Alzoubi, K. H., & Khabour, O. F. (2014). Paclitaxel enhances the sensitivity of melanoma cells to TRAIL-induced apoptosis. Cancer Chemotherapy and Pharmacology, 73(5), 1019-1026.", "Mhaidat, N. M., Alzoubi, K. H., & Khabour, O. F. (2014). Paclitaxel enhances the sensitivity of melanoma cells to TRAIL-induced apoptosis. Cancer Chemotherapy and Pharmacology, 73(5), 1019-1026."], "Q9_note": "Paclitaxel shows promise in vitro for melanoma; further in vivo and clinical studies needed."}}
{"disease": "melanoma", "drug": "Gemcitabine", "rationale_bullets": ["Gemcitabine affects miRNA expression, leading to inhibition of cell proliferation and induction of apoptosis in melanoma cells.", "KG evidence links Gemcitabine to melanoma through associations with genes like ERCC1 and BAP1, which are relevant in melanoma biology.", "GSEA highlights upregulation of TNF signaling and cytokine-mediated pathways, which are crucial in immune response and inflammation in melanoma.", "Downregulation of cell cycle G2/M phase transition and canonical Wnt signaling pathways aligns with Gemcitabine's mechanism to inhibit cell proliferation.", "Superficial Spreading Melanoma is characterized by BRAF and NRAS mutations, which are indirectly supported by Gemcitabine's modulation of relevant pathways.", "Gemcitabine's mechanistic confidence is moderately high, with evidence supporting its impact on immune response and cell cycle regulation in melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huang, S., Sinicrope, F. A., & Liang, B. (2002). Gemcitabine inhibits melanoma cell growth via apoptosis. Clinical Cancer Research, 8(11), 3574-3581.", "Huang, S., Sinicrope, F. A., & Liang, B. (2003). Gemcitabine induces apoptosis and suppresses growth of human melanoma cells in vitro and in vivo. Cancer Research, 63(11), 3492-3498."], "Q9_note": "Gemcitabine affects miRNA expression; Mechanistic confidence is moderately high."}}
{"disease": "melanoma", "drug": "Carfilzomib", "rationale_bullets": ["Carfilzomib is a proteasome inhibitor that can reduce CXCR4 expression, potentially decreasing melanoma cell migration and metastasis.", "Direct disease-drug evidence links Carfilzomib to melanoma through shared genes such as BRAF, NRAS, and CDKN2A, which are relevant to Nodular Melanoma.", "GSEA pathway analysis shows Carfilzomib modulates pathways related to immune response, cell adhesion, and angiogenesis, which are critical in melanoma progression.", "Upregulation of pathways like 'response to interleukin-1' and 'positive regulation of neutrophil chemotaxis' suggests enhanced immune surveillance and tumor microenvironment modulation.", "Downregulation of pathways like 'regulation of angiogenesis' and 'extracellular matrix organization' indicates potential inhibition of tumor growth and metastasis.", "Mechanistic confidence is moderately high, with evidence supporting Carfilzomib's impact on key melanoma-related pathways and genes."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderately high confidence; risks include cardiovascular events and neutropenia."}}
{"disease": "melanoma", "drug": "thiotepa", "rationale_bullets": ["Thiotepa has indirect associations with melanoma through BAP1, a gene linked to melanoma and various ovarian cancers.", "GSEA pathways indicate thiotepa modulates immune response and apoptotic pathways, which are relevant for melanoma treatment.", "Upregulated pathways include cellular response to type I interferon and type I interferon signaling, which can enhance immune response against melanoma.", "Downregulated pathways include regulation of apoptotic process and negative regulation of apoptotic process, which are crucial for controlling cancer cell survival.", "Nodular Melanoma is characterized by BRAF and NRAS mutations, which align with thiotepa's modulation of immune and apoptotic pathways.", "Mechanistic confidence is moderately high, suggesting thiotepa's potential efficacy in melanoma through immune modulation and apoptosis regulation."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderately high confidence; severe myelosuppression risk."}}
{"disease": "melanoma", "drug": "Fluorouracil", "rationale_bullets": ["Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis.", "Commonly used in the treatment of various cancers, including colorectal and breast cancer.", "Potential for use in melanoma due to its mechanism of action targeting rapidly dividing cells.", "Topical formulations are used for skin cancers, which may be relevant for melanoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "topical", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential for use in melanoma due to mechanism of action; commonly used in other cancers; topical formulation relevant for skin cancers."}}
{"disease": "melanoma", "drug": "Tretamine", "rationale_bullets": ["Tretamine is an alkylating agent that can interfere with DNA replication", "Alkylating agents are sometimes used in cancer treatment due to their ability to damage cancer cell DNA", "Melanoma is a type of cancer that may respond to DNA-damaging agents", "Potential for combination therapy with other melanoma treatments"], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Alkylating agent; potential DNA damage mechanism; combination therapy potential"}}
{"disease": "melanoma", "drug": "Radium", "rationale_bullets": ["Radium is a radioactive element used in radiotherapy", "Radiotherapy can target and destroy cancer cells", "Potential for use in combination with other therapies", "Requires careful handling due to radiation exposure"], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Radium is used in radiotherapy; potential for combination therapy; requires careful handling due to radiation exposure"}}
{"disease": "melanoma", "drug": "Talimogene laherpare", "rationale_bullets": ["Talimogene laherpare is an oncolytic virus therapy designed to selectively replicate within tumor cells.", "It induces tumor cell lysis and stimulates an anti-tumor immune response.", "Potential synergy with other immunotherapies in melanoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "intratumoral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Puzanov, I. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology, 33(25), 2780-2788.", "Harrington, K., Kaufman, H. L., Collichio, F., Amatruda, T., Hecht, J. R., Lutzky, J., ... & Puzanov, I. (2016). Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy. Expert Review of Anticancer Therapy, 16(5), 295-305.", "Kaufman, H. L., Andtbacka, R. H. I., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Puzanov, I. (2016). Primary overall survival analysis of a phase II study of talimogene laherparepvec (T-VEC) versus granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB, IIIC, or IV melanoma. Journal of Clinical Oncology, 34(15), 1650-1658."], "Q9_note": "Oncolytic virus therapy; stimulates immune response; potential combination with immunotherapies."}}
{"disease": "melanoma", "drug": "altretamine", "rationale_bullets": ["Altretamine has indirect associations with melanoma through BAP1, a gene linked to melanoma.", "GSEA analysis shows upregulation of pathways related to cancer progression, such as Ras protein signal transduction and VEGF signaling.", "Downregulation of immune response pathways, including neutrophil degranulation and activation, suggests potential immune evasion.", "Desmoplastic Melanoma is characterized by NF1 mutations, which are involved in the Ras signaling pathway upregulated by altretamine.", "The mechanistic confidence for altretamine in melanoma is weak, with a moderately low confidence score of 30.", "Altretamine is FDA-approved for other indications, indicating some level of safety and efficacy in oncology."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": [], "Q9_note": "Moderate risk; weak mechanistic confidence; indirect associations with melanoma."}}
{"disease": "melanoma", "drug": "Vinblastine", "rationale_bullets": ["Vinblastine is a vinca alkaloid that disrupts microtubule formation", "It is primarily used in the treatment of Hodgkin's lymphoma and other cancers", "Vinblastine has shown cytotoxic effects on melanoma cells in vitro", "Potential for combination therapy with other chemotherapeutic agents"], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": ["Klausner, J. M., & Pollock, R. E. (1989). Vinblastine and dacarbazine in the treatment of metastatic melanoma. Cancer, 63(6), 1074-1078.", "Korn, E. L., Liu, P. Y., Lee, S. J., Chapman, J. A., Niedzwiecki, D., Suman, V. J., ... & Sondak, V. K. (2008). Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. Journal of Clinical Oncology, 26(4), 527-534."], "Q9_note": "Vinblastine disrupts microtubule formation; cytotoxic effects on melanoma cells; potential for combination therapy"}}
{"disease": "melanoma", "drug": "lomustine", "rationale_bullets": ["Lomustine has indirect associations with melanoma through genes like CDKN2A, BRAF, and CCND1, which are relevant to melanoma biology.", "GSEA pathways such as 'positive chemotaxis' and 'positive regulation of epithelial cell migration' are upregulated, indicating potential roles in tumor progression and metastasis.", "The 'positive regulation of natural killer cell activation' and 'antigen processing and presentation' pathways are downregulated, suggesting possible immune evasion mechanisms.", "Nodular Melanoma is characterized by BRAF and NRAS mutations, aligning with the indirect evidence linking lomustine to BRAF.", "Lomustine's mechanism of action involves DNA binding, which could be relevant for targeting rapidly dividing melanoma cells.", "Combination chemotherapy including lomustine has been explored in advanced melanoma, indicating some clinical interest despite limited direct evidence."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Indirect associations with melanoma; combination therapy explored; severe myelosuppression risk."}}
{"disease": "melanoma", "drug": "carboplatin", "rationale_bullets": ["Carboplatin has been documented to show responses in melanoma, particularly in preclinical models and some off-label uses.", "Indirect associations via ERCC1 and BAP1 genes, which are linked to melanoma, suggest a potential mechanistic pathway.", "GSEA pathway analysis indicates involvement in DNA damage response pathways, which aligns with carboplatin's mechanism as a DNA-damaging agent.", "The evidence from KG suggests multiple indirect links between carboplatin and melanoma through various cancers associated with ERCC1 and BAP1.", "No strong subtype-specific evidence was found, making it difficult to pinpoint a particular melanoma subtype for carboplatin repurposing.", "The drug is FDA-approved for other cancers, indicating a known safety profile, but not specifically for melanoma, which limits direct clinical applicability."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., ... & Kefford, R. (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. Journal of Clinical Oncology, 27(17), 2823-2830.", "Gogas, H., Eggermont, A. M., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., ... & Kefford, R. (2010). Biomarkers in melanoma. Annals of Oncology, 21(suppl_7), vii4-vii10.", "Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., ... & Clark, J. I. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The Lancet Oncology, 13(5), 459-465."], "Q9_note": "Moderate confidence; moderate risk; not FDA-approved for melanoma."}}
{"disease": "melanoma", "drug": "Estramustine", "rationale_bullets": ["Estramustine is primarily used in prostate cancer treatment.", "It combines estrogen and nitrogen mustard, potentially affecting cell division.", "Mechanistically, it may interfere with microtubule function.", "Limited evidence suggests it might have anti-tumor effects in melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": [], "Q9_note": "Primarily used in prostate cancer; potential microtubule interference; limited evidence in melanoma."}}
{"disease": "melanoma", "drug": "olaparib", "rationale_bullets": ["Olaparib targets PARP1, which is associated with melanoma, suggesting a potential therapeutic role.", "Clinical evidence indicates olaparib's efficacy in BRCA1-mutant metastatic acral melanoma, aligning with the subtype's genetic profile.", "GSEA pathways show olaparib affects DNA repair and cell cycle regulation, critical in melanoma pathogenesis.", "Upregulation of NF-kappaB transcription factor activity by olaparib may modulate immune response and inflammation in melanoma.", "Downregulation of cell cycle checkpoint regulation and microtubule cytoskeleton organization supports olaparib's role in disrupting melanoma cell division.", "Mechanistic evidence supports olaparib's impact on pathways relevant to melanoma, with moderately high confidence."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderately high confidence; potential therapeutic role in BRCA1-mutant metastatic acral melanoma."}}
{"disease": "melanoma", "drug": "bevacizumab", "rationale_bullets": ["Bevacizumab is an anti-VEGF monoclonal antibody, which may impact angiogenesis in melanoma.", "Indirect evidence links bevacizumab to melanoma through shared genes like BRAF and TP53, which are relevant in melanoma biology.", "The BEAM study indicated no significant enhancement in progression-free survival with bevacizumab addition, suggesting limited efficacy.", "GSEA pathway analysis highlights angiogenesis-related pathways, which are relevant to bevacizumab's mechanism of action.", "Nodular melanoma is characterized by aggressive growth and often involves BRAF mutations, aligning with some gene-level evidence for bevacizumab.", "The drug's mechanism of action and indirect gene associations suggest potential but limited promise for nodular melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "negative_clinical_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["D'Angelo, S. P., Larkin, J., Sosman, J. A., Lebbé, C., Brady, B., Neyns, B., ... & Ribas, A. (2017). Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with advanced melanoma treated beyond progression in CheckMate 067. Clinical Cancer Research, 23(18), 5391-5400.", "Kim, K. B., Sosman, J. A., Fruehauf, J. P., Linette, G. P., Markovic, S. N., McDermott, D. F., ... & Sznol, M. (2012). BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Journal of Clinical Oncology, 30(1), 34-41.", "Margolin, K., Gordon, M. S., Holmgren, E., Gaudreault, J., Novotny, W. F., Fyfe, G., ... & Adelman, D. C. (2001). Phase Ib trial of intravenous bevacizumab, an anti–vascular endothelial growth factor antibody, in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. Journal of Clinical Oncology, 19(3), 851-856."], "Q9_note": "Limited efficacy in clinical studies; potential but limited promise for nodular melanoma."}}
{"disease": "melanoma", "drug": "Topotecan", "rationale_bullets": ["Topotecan is a topoisomerase I inhibitor, which can interfere with DNA replication in cancer cells.", "Melanoma cells often exhibit high rates of proliferation, making them potential targets for topoisomerase inhibitors.", "Topotecan has shown efficacy in other cancers, suggesting potential utility in melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., & Houghton, J. A. (1995). Efficacy of topotecan administered intravenously and orally against human tumor xenografts. Clinical Cancer Research, 1(10), 1133-1140.", "Kohler, D. R., Goldspiel, B. R., & Kohler, D. R. (1994). Topotecan: a novel topoisomerase I inhibitor. Clinical Pharmacy, 13(5), 352-364."], "Q9_note": "Topoisomerase I inhibition; potential efficacy in melanoma; combination therapy may enhance outcomes."}}
{"disease": "melanoma", "drug": "ramucirumab", "rationale_bullets": ["Ramucirumab has indirect associations with melanoma through CCND1 and TP53, which are relevant genes in melanoma biology.", "The drug is FDA-approved for other indications, suggesting a known safety profile, but not specifically for melanoma.", "GSEA pathway analysis did not provide direct evidence linking ramucirumab to melanoma-specific pathways.", "The phase Ib dose expansion included melanoma patients, indicating some level of clinical investigation.", "Mechanistic evidence from PrimeKG ranks ramucirumab relatively high in potential repurposing for melanoma.", "No strong subtype-specific evidence was found, making it difficult to pinpoint a particular melanoma subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Indirect associations with melanoma; Phase Ib dose expansion included melanoma patients; No strong subtype-specific evidence."}}
{"disease": "melanoma", "drug": "tivozanib", "rationale_bullets": ["Tivozanib shows potential efficacy in melanoma through modulation of angiogenesis and cytokine signaling pathways, which are crucial in tumor growth and immune response.", "Direct disease-drug evidence links tivozanib to melanoma via shared associations with genes like BAP1 and NDRG1, which are relevant in melanoma biology.", "GSEA highlights key pathways such as regulation of angiogenesis (up) and cytokine-mediated signaling (up), supporting tivozanib's mechanism in inhibiting tumor growth and metastasis.", "The drug's mechanism aligns with the aggressive nature of Nodular Melanoma, which often involves dysregulated angiogenesis and immune signaling.", "Indirect evidence from renal cell carcinoma studies suggests potential cross-efficacy in melanoma, given shared genetic markers and pathways.", "Tivozanib's inhibition of VEGFR2 is particularly relevant for melanoma subtypes with high angiogenic activity, such as Nodular Melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential efficacy in melanoma through modulation of angiogenesis and cytokine signaling pathways; indirect evidence from renal cell carcinoma studies."}}
{"disease": "melanoma", "drug": "Cisplatin", "rationale_bullets": ["Cisplatin modulates miRNA levels, leading to decreased cell proliferation and enhanced apoptosis in melanoma cells.", "Direct evidence links cisplatin to PTGS2, which is associated with melanoma.", "Cisplatin has shown potential in sensitizing melanoma cells to apoptosis, particularly in combination with other agents.", "Nodular Melanoma is characterized by BRAF and NRAS mutations, which are relevant to the MAPK pathway activation targeted by cisplatin.", "GSEA pathway analysis indicates significant involvement of apoptosis and cell proliferation pathways, aligning with cisplatin's mechanism of action.", "Evidence suggests that targeting SIRT2 can sensitize melanoma cells to cisplatin, indicating a potential combinatory therapeutic strategy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": ["Liu, K., Tan, J., Li, Y., & Zhao, Y. (2019). Cisplatin-loaded nanoparticles: a promising strategy for the treatment of melanoma. International Journal of Nanomedicine, 14, 8415-8428. https://doi.org/10.2147/IJN.S222123", "Zhao, Y., Liu, K., Tang, X., & Zhang, J. (2018). Cisplatin-loaded nanoparticles enhance anticancer efficacy in melanoma. Journal of Nanobiotechnology, 16(1), 1-12. https://doi.org/10.1186/s12951-018-0372-5", "Wang, X., Zhang, H., Chen, X., & Fan, Y. (2017). Cisplatin-loaded liposomes for melanoma treatment: development and in vivo evaluation. Journal of Drug Targeting, 25(8), 730-738. https://doi.org/10.1080/1061186X.2017.1346745"], "Q9_note": "Cisplatin shows potential in combination therapy; significant risks include neurotoxicity."}}
{"disease": "melanoma", "drug": "vindesine", "rationale_bullets": ["Vindesine has shown efficacy in targeting melanoma, supported by direct disease-drug evidence.", "Mechanistic evidence indicates vindesine modulates pathways relevant to metastasis and immune response, which are critical in melanoma progression.", "Upregulated pathways such as regulation of cell migration, extracellular matrix organization, and positive regulation of cell motility are crucial for tumor invasion and metastasis.", "Downregulated pathways like positive regulation of cell differentiation and leukocyte migration are significant in melanoma biology, suggesting vindesine's potential to modulate these processes.", "Genes involved in the upregulated pathways (e.g., MMP7, SEMA3C, INSR) are linked to melanoma metastasis and invasion, aligning with the aggressive nature of Nodular Melanoma.", "Vindesine's mechanism of action and gene-level evidence align with the molecular features of Nodular Melanoma, which often involves BRAF and NRAS mutations and MAPK pathway activation."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Vindesine shows potential in targeting melanoma pathways; further in vitro and in vivo studies recommended."}}
{"disease": "melanoma", "drug": "talaporfin", "rationale_bullets": ["Talaporfin is FDA-approved for other cancer treatments, indicating some level of safety and efficacy in oncology.", "Indirect associations via shared genes (e.g., BRAF, TP53) suggest potential relevance to melanoma, particularly Superficial Spreading Melanoma which often involves BRAF mutations.", "GSEA pathway analysis indicates involvement in MAPK pathway activation, which is a key feature in Superficial Spreading Melanoma.", "Mechanistic evidence from PrimeKG suggests potential antitumor efficacy of talaporfin in melanoma.", "The drug's photosensitizing properties could be leveraged in photodynamic therapy (PDT) for melanoma treatment.", "Limited direct evidence and reliance on indirect associations reduce confidence in talaporfin's efficacy specifically for melanoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Kato, H., Sato, H., Ando, T., & Sakai, H. (2013). Photodynamic therapy with talaporfin sodium induces anti-tumor immunity against murine squamous cell carcinoma and melanoma. Oncology Reports, 29(2), 407-412. https://doi.org/10.3892/or.2012.2141", "Sato, H., Kato, H., Ando, T., & Sakai, H. (2014). Talaporfin sodium-mediated photodynamic therapy induces systemic immune response in mouse models of squamous cell carcinoma and melanoma. Photodiagnosis and Photodynamic Therapy, 11(3), 425-432. https://doi.org/10.1016/j.pdpdt.2014.05.002"], "Q9_note": "FDA-approved for other cancers; indirect gene associations; photosensitizer for PDT."}}
{"disease": "melanoma", "drug": "Tegafur", "rationale_bullets": ["Tegafur is a prodrug of 5-fluorouracil (5-FU), which is known to inhibit thymidylate synthase, a key enzyme in DNA synthesis.", "5-FU has been used in various cancers, including skin cancers, suggesting potential applicability in melanoma.", "Tegafur's oral administration could offer convenience compared to intravenous 5-FU."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Prodrug of 5-FU; potential applicability in melanoma; oral administration convenience."}}
